

Innovation all for the patients



Roche A member of the Roche group

Roche Announces Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

TOKYO, May 11, 2022 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that Roche issued a press release regarding interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer of the investigational anti-TIGIT immunotherapy tiragolumab.

Please refer to the link below for details of the press release:

Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer

<https://www.roche.com/media/releases/med-cor-2022-05-11>

###